Herceptin sBLA Submitted For Early-Stage Use
This article was originally published in The Pink Sheet Daily
Executive Summary
A supplemental BLA for an early adjuvant breast cancer indication for Herceptin will have a mid-August user fee date, if granted priority review
You may also be interested in...
Herceptin early-stage breast cancer user fee date extended
New deadline is November after Genentech provides FDA with additional analyses of previously submitted studies.
Herceptin early-stage breast cancer user fee date extended
New deadline is November after Genentech provides FDA with additional analyses of previously submitted studies.
Herceptin Less-Frequent Dosing Is Preferred For Early-Stage Breast Cancer, NICE Says
U.K.’s NICE supports adoption of three-week interval dosing for trastuzumab for early-stage HER2-positive breast cancer.